APA (7th ed.) Citation

S, B., MB, H., HB, S., S, E. M., MM, H., MR, M., . . . F, S. (2026). Residual inflammation in the cerebrospinal fluid after short- and long-term natalizumab treatment in relapsing-remitting multiple sclerosis. Frontiers in immunology, 17, 1817671. https://doi.org/10.3389/fimmu.2026.1817671

Chicago Style (17th ed.) Citation

S, Buhelt, Hansen MB, Søndergaard HB, El Mahdaoui S, Hansen MM, Mahler MR, Romme Christensen J, and Sellebjerg F. "Residual Inflammation in the Cerebrospinal Fluid After Short- and Long-term Natalizumab Treatment in Relapsing-remitting Multiple Sclerosis." Frontiers in Immunology 17 (2026): 1817671. https://doi.org/10.3389/fimmu.2026.1817671.

MLA (9th ed.) Citation

S, Buhelt, et al. "Residual Inflammation in the Cerebrospinal Fluid After Short- and Long-term Natalizumab Treatment in Relapsing-remitting Multiple Sclerosis." Frontiers in Immunology, vol. 17, 2026, p. 1817671, https://doi.org/10.3389/fimmu.2026.1817671.